Drug Profile
Research programme: antifibrotics - Blade Therapeutics
Latest Information Update: 28 Jul 2021
Price :
$50
*
At a glance
- Originator Blade Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Calpain inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Fibrosis in USA (PO)
- 18 Oct 2017 Blade Therapeutics intends to initiate clinical development for its lead candidate in mid 2018
- 20 Jun 2017 Blade Therapeutics plans IND-enabling studies for Fibrosis by end of 2017